Top

Published in:

01-09-2013 | Original Article

CC chemokine receptor 5 polymorphism in Italian patients with giant cell arteritis

Authors: Giulia Pazzola, Luigi Boiardi, Bruno Casali, Enrico Farnetti, Davide Nicoli, Nicolò Pipitone, Ilaria Padovano, Andrea Caruso, Mariagrazia Catanoso, Carlo Salvarani

Published in: Modern Rheumatology | Issue 5/2013

Abstracts

Objectives

To evaluate the potential role of CC chemokine receptor 5 (CCR5)Δ32 polymorphism in the susceptibility to giant cell arteritis (GCA) in a cohort of Italian patients.

Methods

176 consecutive Italian patients with biopsy-proven GCA and 180 healthy age- and sex-matched blood donors were molecularly genotyped for the CCR5Δ32 polymorphism.

Results

No statistically significant difference in the Δ32CCR5 allele frequency between GCA patients (5.1 %) and controls (2.8 %) was observed (p = 0.109). Carriers of the CCR5Δ32 allele (Δ32/Δ32 + CCR5/Δ32) were similarly represented in the two groups.

Conclusions

Our results do not support a role for the CCR5Δ32 polymorphism in determining susceptibility to GCA.

Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, Miranda-Filloy JA, Gonzalez-Juanatey C, Martin J, et al. Epidemiology of giant cell arteritis and polymialgia rheumatica. Arthritis Rheum. 2009;61:1454–61.PubMedCrossRef

Gonzalez-Gay MA, Amoli MM, Garcia-Porrua C, Ollier WR. Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. Semin Arthritis Rheum. 2003;33:38–48.PubMedCrossRef

Weyand CM, Hicok KC, Hunder GG, Goronzy J. The HLA-DRB1 locus as a genetic component in giant cell arteritis. Mapping of a disease-linked sequence motif to the antigen binding site of the HLA-DR molecule. J Clin Invest. 1992;90:2355–61.PubMedCrossRef

Boiardi L, Casali B, Farnetti E, Pipitone N, Nicoli D, Macchioni P, et al. Interleukin-10 promoter polymorphisms in giant cell arteritis. Arthritis Rheum. 2006;54:4011–7.PubMedCrossRef

Salvarani C, Casali B, Nicoli D, Farnetti E, Macchioni P, Catanoso MG, et al. Endothelial nitric oxide synthase gene polymorphisms in giant cell arteritis. Arthritis Rheum. 2003;48:3219–23.PubMedCrossRef

Ward SG, Marelli-Berg FM. Mechanisms of chemokine and antigen-dependent T-lymphocyte navigation. Biochem J. 2009;418:13–27.PubMedCrossRef

Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006;354:610–21.PubMedCrossRef

Mueller A, Strange PG. The chemokine receptor, CCR5. Int J Biochem Cell Biol. 2004;36:35–8.PubMedCrossRef

Brühl H, Vielhauer V, Weiss M, Mack M, Schlöndorff D, Segerer S. Expression of DARC, CXCR3 and CCR5 in giant cell arteritis. Rheumatology. 2005;44:309–13.PubMedCrossRef

10.

O’Brien SJ, Moore JP. The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol Rev. 2000;177:99–111.PubMedCrossRef

11.

Martens HA, Kallenberg CG, Bijl M. Role of CCR5 delta32 bp deletion in RA and SLE. Autoimmunity. 2009;42:260–2.

12.

Petrek M, Gibejova A, Drabek J, Mrazek F, Kolek V, Weigl E, et al. CC chemokine receptor 5 (CCR5) mRNA expression in pulmonary sarcoidosis. Immunol Lett. 2002;80(189):93.

13.

Kantor R, Bakhanashvili M, Achiron A. A mutated CCR5 gene may have favorable prognostic implications in MS. Neurology. 2003;61(238):40.

14.

Carmona FD, Rodríguez-Rodríguez L, Castañeda S, Miranda-Filloy JA, Morado IC, Narváez J, et al. Role of the CCR5/Δ32CCR5 polymorphism in biopsy-proven giant cell arteritis. Hum Immunol. 2011;72:458–61.PubMedCrossRef

15.

Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, Gonzalez-Louzao C, Rodriguez-Ledo P. Biopsy-negative giant cell arteritis: clinical spectrum and predictive factors for positive temporal artery biopsy. Semin Arthritis Rheum. 2001;30:249–56.PubMedCrossRef

16.

Restuccia G, Cavazza A, Boiardi L, Pipitone N, Macchioni P, Bajocchi G, et al. Small-vessel vasculitis surrounding an uninflamed temporal artery and isolated vasa vasorum vasculitis of the temporal artery: two subsets of giant cell arteritis. Arthritis Rheum. 2012;64:549–56.PubMedCrossRef

17.

Yang B, Houlberg K, Millward A, Demaine A. Polymorphisms of chemokine and chemokine receptors in type 1 diabetes mellitus and its complications. Cytokine. 2004;26:114–21.PubMedCrossRef

18.

Odum N, Bregenholt S, Eriksen KW, Skov S, Ryder LP, Bendtzen K, et al. The CC-chemokine receptor 5 (CCR5) is a marker of, but not essential for the development of human Th1 cells. Tissue Antigens. 1999;54:572–7.PubMedCrossRef

19.

Berce V, Repnik K, Potocnik U. Association of CCR5-delta32 mutation with reduced risk of nonatopic asthma in Slovenian children. J Asthma. 2008;45:780–4.PubMedCrossRef

20.

Petrek M, Cermáková Z, Hutyrová B, Miceková D, Drábek J, Rovensky J, et al. CC chemokine receptor 5 and interleukin-1 receptor antagonist gene polymorphisms in patients with primary Sjögren’s syndrome. Clin Exp Rheumatol. 2002;20:701–3.PubMed

21.

Pokorny V, McQueen F, Yeoman S, Merriman M, Merriman A, Harrison A, et al. Evidence for negative association of the chemokine receptor CCR5 d32 polymorphism with rheumatoid arthritis. Ann Rheum Dis. 2005;64:487–90.PubMedCrossRef

22.

Zhou Y, Huang D, Farver C, Hoffman GS. Relative importance of CCR5 and antineutrophil cytoplasmic antibodies in patients with Wegener’s granulomatosis. J Rheumatol. 2003;30:1541–7.PubMed

23.

Petrek M, Drábek J, Kolek V, Zlámal J, Welsh KI, Bunce M, et al. CC chemokine receptor gene polymorphisms in Czech patients with pulmonary sarcoidosis. Am J Respir Crit Care Med. 2000;162:1000–3.PubMedCrossRef

24.

Atzeni F, Boiardi L, Casali B, Farnetti E, Sarzi-Puttini PC, Pipitone N et al. CC Chemokine receptor 5 polymorphism in italian patients with Behçet’s disease. Rhematology 2012 (in press).

25.

Boiardi L, Vaglio A, Nicoli D, Farnetti E, Palmisano A, Pipitone N, et al. CC chemokine receptor 5 polymorphism in chronic periaortitis. Rheumatology. 2011;50:1025–32.PubMedCrossRef

26.

Ghilardi G, Biondi ML, Battaglioli L, Zambon A, Guagnellini E, Scorza R. Genetic risk factor characterizes abdominal aortic aneurysm from arterial occlusive disease in human beings: CCR5 Delta 32 deletion. J Vasc Surg. 2004;40:995–1000.PubMedCrossRef

27.

Salvarani C, Boiardi L, Timms JM, Silvestri T, Ranzi A, Macchioni PL, et al. Absence of the association with CC chemokine receptor 5 polymorphism in polymyalgia rheumatica. Clin Exp Rheumatol. 2000;18:591–5.PubMed

28.

Zhou Y, Kurihara T, Ryseck RP, Yang Y, Ryan C, Loy J, et al. Impaired macrophage function and enhanced T cell-dependent immune response in mice lacking CCR5, the mouse homologue of the major HIV-1 coreceptor. J Immunol. 1998;160:4018–25.PubMed

29.

Ajuebor MN, Wondimu Z, Hogaboam CM, Le T, Proudfoot AE, Swain MG. CCR5 deficiency drives enhanced natural killer cell trafficking to and activation within the liver in murine T cell-mediated hepatitis. Am J Pathol. 2007;170:1975–88.PubMedCrossRef

30.

Takeuchi A, Usui Y, Takeuchi M, Hattori T, Kezuka T, et al. CCR5-deficient mice develop experimental autoimmune uveoretinitis in the context of a deviant effector response. Invest Ophthalmol Vis Sci. 2005;46:3753–60.PubMedCrossRef

31.

Ramshaw AL, Parums DV. Immunohistochemical characterization of inflammatory cells associated with advanced atherosclerosis. Histopathology. 1990;17:543–52.PubMedCrossRef

32.

Ramshaw AL, Roskell DE, Parums DV. Cytokine gene expression in aortic adventitial inflammation associated with advanced atherosclerosis (chronic periaortitis). J Clin Pathol. 1994;47:721–7.PubMedCrossRef

33.

Weyand CM, Hicok KC, Hunder GG, Goronzy JJ. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med. 1994;121:484–91.PubMedCrossRef

Title: CC chemokine receptor 5 polymorphism in Italian patients with giant cell arteritis
Authors: Giulia Pazzola
Luigi Boiardi
Bruno Casali
Enrico Farnetti
Davide Nicoli
Nicolò Pipitone
Ilaria Padovano
Andrea Caruso
Mariagrazia Catanoso
Carlo Salvarani
Publication date: 01-09-2013
Publisher: Springer Japan
Published in: Modern Rheumatology / Issue 5/2013
Print ISSN: 1439-7595
Electronic ISSN: 1439-7609
DOI: https://doi.org/10.1007/s10165-012-0751-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstracts

Objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2013

Proximal rotational closing-wedge osteotomy of the first metatarsal in rheumatoid arthritis: clinical and radiographic evaluation of a continuous series of 35 cases

Clinical features of patients with anti-neutrophil cytoplasmic autoantibodies targeting native myeloperoxidase antigen

Evaluation of the efficacy and safety of etanercept 50 mg once weekly in Japanese patients with rheumatoid arthritis and comparison with 25 mg etanercept twice weekly

The Japanese version of the modified ACR Preliminary Diagnostic Criteria for Fibromyalgia and the Fibromyalgia Symptom Scale: reliability and validity

Investigations of IgG4-related disease involving the skin

Clinical and laboratory features dependent on age at onset in Japanese systemic sclerosis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials